Clinical Trial Update: A Twelve-Week Study of Varenicline for Safety and Efficacy in Comparison With Placebo for Smoking Cessation [Phase 3]

View source ↗

Summary

A twelve-week Phase 3 trial comparing varenicline to placebo for smoking cessation demonstrated safety and efficacy. The study was sponsored by Pfizer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nicotine Dependence

Drugs mentioned

• Varenicline (varenicline)

Snippet

Sponsor: Pfizer | Conditions: Smoking Cessation | Phase 3 | Status: COMPLETED